Peripheral and Tumor-infiltrating Immune Cells Are Correlated with Patient Outcomes in Ovarian Cancer

Overview

Journal Cancer Med

Specialty Oncology

Date 2023 Jan 16

PMID 36645174

Authors

Weiwei Zhang

Yawen Ling

Zhidong Li

Xingchen Peng

Yazhou Ren

Affiliations

Soon will be listed here.

Abstract

Objective: At present, there is still a lack of reliable biomarkers for ovarian cancer (OC) to guide prognosis prediction and accurately evaluate the dominant population of immunotherapy. In recent years, the relationship between peripheral blood markers and tumor-infiltrating immune cells (TICs) with cancer has attracted much attention. However, the relationship between the survival of OC patients and intratumoral- or extratumoral-associated immune cells remains controversial.

Methods: In this study, four machine-learning algorithms were used to predict overall survival in OC patients based on peripheral blood indicators. To further screen out immune-related gene and molecular targets, we systematically explored the correlation between TICs and OC patient survival based on The Cancer Genome Atlas database. Using the TICs score method, patients were divided into a low immune infiltrating cell group and a high immune infiltrating cell group.

Results: The results showed that there was a significant statistical significance between the peripheral blood indicators and the survival prognosis of OC patients. Survival analysis showed that TICs play a crucial role in the survival of OC patients. Four core genes, CXCL9, CD79A, MS4A1, and MZB1, were identified by cross-PPI and COX regression analysis. Further analysis found that these genes were significantly associated with both TICs and survival in OC patients.

Conclusions: These results suggest that both peripheral blood markers and TICs can be used as prognostic predictors in patients with OC, and CXCL9, CD79A, MS4A1, and MZB1 may be potential therapeutic targets for OC immunotherapy.

Citing Articles

MS4A superfamily molecules in tumors, Alzheimer's and autoimmune diseases.

Luo X, Luo B, Fei L, Zhang Q, Liang X, Chen Y Front Immunol. 2024; 15:1481494.

PMID: 39717774 PMC: 11663944. DOI: 10.3389/fimmu.2024.1481494.

Exploring immune status in peripheral blood and tumor tissue in association with survival in patients with multi-organ metastatic colorectal cancer.

Bakkerus L, Subtil B, Bontkes H, Gootjes E, Reijm M, Vullings M Oncoimmunology. 2024; 13(1):2361971.

PMID: 38868078 PMC: 11168219. DOI: 10.1080/2162402X.2024.2361971.

Peripheral and tumor-infiltrating immune cells are correlated with patient outcomes in ovarian cancer.

Zhang W, Ling Y, Li Z, Peng X, Ren Y Cancer Med. 2023; 12(8):10045-10061.

PMID: 36645174 PMC: 10166954. DOI: 10.1002/cam4.5590.

References

Kandalaft L, Powell Jr D, Singh N, Coukos G . Immunotherapy for ovarian cancer: what's next?. J Clin Oncol. 2010; 29(7):925-33. PMC: 3068064. DOI: 10.1200/JCO.2009.27.2369. View

Fan L, Lei H, Lin Y, Zhou Z, Shu G, Yan Z . Identification of a Gene Set Correlated With Immune Status in Ovarian Cancer by Transcriptome-Wide Data Mining. Front Mol Biosci. 2021; 8:670666. PMC: 8363306. DOI: 10.3389/fmolb.2021.670666. View

Guo P, Wang P, Zhou J, Jiang S, Patel V . Multi-institutional Collaborations for Improving Deep Learning-based Magnetic Resonance Image Reconstruction Using Federated Learning. Proc IEEE Comput Soc Conf Comput Vis Pattern Recognit. 2022; 2021:2423-2432. PMC: 9017654. DOI: 10.1109/cvpr46437.2021.00245. View

Siravegna G, Marsoni S, Siena S, Bardelli A . Integrating liquid biopsies into the management of cancer. Nat Rev Clin Oncol. 2017; 14(9):531-548. DOI: 10.1038/nrclinonc.2017.14. View

Samstein R, Lee C, Shoushtari A, Hellmann M, Shen R, Janjigian Y . Tumor mutational load predicts survival after immunotherapy across multiple cancer types. Nat Genet. 2019; 51(2):202-206. PMC: 6365097. DOI: 10.1038/s41588-018-0312-8. View

Mudd Jr T, Lu C, Klement J, Liu K . MS4A1 expression and function in T cells in the colorectal cancer tumor microenvironment. Cell Immunol. 2020; 360:104260. PMC: 7855947. DOI: 10.1016/j.cellimm.2020.104260. View

Kim S, Song M, Hwangbo S, Lee S, Cho U, Kim J . Development of Web-Based Nomograms to Predict Treatment Response and Prognosis of Epithelial Ovarian Cancer. Cancer Res Treat. 2018; 51(3):1144-1155. PMC: 6639233. DOI: 10.4143/crt.2018.508. View

Liu R, Wei H, Gao P, Yu H, Wang K, Fu Z . CD47 promotes ovarian cancer progression by inhibiting macrophage phagocytosis. Oncotarget. 2017; 8(24):39021-39032. PMC: 5503592. DOI: 10.18632/oncotarget.16547. View

Antonia S, Villegas A, Daniel D, Vicente D, Murakami S, Hui R . Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer. N Engl J Med. 2017; 377(20):1919-1929. DOI: 10.1056/NEJMoa1709937. View

10.

Gros A, Parkhurst M, Tran E, Pasetto A, Robbins P, Ilyas S . Prospective identification of neoantigen-specific lymphocytes in the peripheral blood of melanoma patients. Nat Med. 2016; 22(4):433-8. PMC: 7446107. DOI: 10.1038/nm.4051. View

11.

Ferris R, Blumenschein Jr G, Fayette J, Guigay J, Colevas A, Licitra L . Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck. N Engl J Med. 2016; 375(19):1856-1867. PMC: 5564292. DOI: 10.1056/NEJMoa1602252. View

12.

Motzer R, Escudier B, Mcdermott D, George S, Hammers H, Srinivas S . Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. N Engl J Med. 2015; 373(19):1803-13. PMC: 5719487. DOI: 10.1056/NEJMoa1510665. View

13.

Farolfi A, Gurioli G, Fugazzola P, Burgio S, Casanova C, Ravaglia G . Immune System and DNA Repair Defects in Ovarian Cancer: Implications for Locoregional Approaches. Int J Mol Sci. 2019; 20(10). PMC: 6566239. DOI: 10.3390/ijms20102569. View

14.

Chaudhuri A, Chabon J, Lovejoy A, Newman A, Stehr H, Azad T . Early Detection of Molecular Residual Disease in Localized Lung Cancer by Circulating Tumor DNA Profiling. Cancer Discov. 2017; 7(12):1394-1403. PMC: 5895851. DOI: 10.1158/2159-8290.CD-17-0716. View

15.

Bottoni P, Scatena R . The Role of CA 125 as Tumor Marker: Biochemical and Clinical Aspects. Adv Exp Med Biol. 2015; 867:229-44. DOI: 10.1007/978-94-017-7215-0_14. View

16.

Zhang L, Wang Y, Ju J, Shabanova A, Li Y, Fang R . Mzb1 protects against myocardial infarction injury in mice via modulating mitochondrial function and alleviating inflammation. Acta Pharmacol Sin. 2020; 42(5):691-700. PMC: 8115150. DOI: 10.1038/s41401-020-0489-0. View

17.

El-Khoueiry A, Sangro B, Yau T, Crocenzi T, Kudo M, Hsu C . Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. Lancet. 2017; 389(10088):2492-2502. PMC: 7539326. DOI: 10.1016/S0140-6736(17)31046-2. View

18.

Danilova L, Wang H, Sunshine J, Kaunitz G, Cottrell T, Xu H . Association of PD-1/PD-L axis expression with cytolytic activity, mutational load, and prognosis in melanoma and other solid tumors. Proc Natl Acad Sci U S A. 2016; 113(48):E7769-E7777. PMC: 5137776. DOI: 10.1073/pnas.1607836113. View

19.

Zhu A, Finn R, Edeline J, Cattan S, Ogasawara S, Palmer D . Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial. Lancet Oncol. 2018; 19(7):940-952. DOI: 10.1016/S1470-2045(18)30351-6. View

20.

Luo X, Xu J, Yu J, Yi P . Shaping Immune Responses in the Tumor Microenvironment of Ovarian Cancer. Front Immunol. 2021; 12:692360. PMC: 8261131. DOI: 10.3389/fimmu.2021.692360. View